KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Capital Expenditures: 2011-2025

Historic Capital Expenditures for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $129,000.

  • Supernus Pharmaceuticals' Capital Expenditures fell 35.50% to $129,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 136.13%. This contributed to the annual value of $725,000 for FY2024, which is 31.58% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Capital Expenditures is $129,000, which was down 71.65% from $455,000 recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Capital Expenditures ranged from a high of $851,000 in Q1 2022 and a low of -$271,000 during Q2 2022.
  • Its 3-year average for Capital Expenditures is $198,818, with a median of $200,000 in 2024.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Capital Expenditures slumped by 67.33% in 2023 and then skyrocketed by 691.67% in 2024.
  • Over the past 4 years, Supernus Pharmaceuticals' Capital Expenditures (Quarterly) stood at -$168,000 in 2022, then spiked by 78.57% to -$36,000 in 2023, then soared by 691.67% to $213,000 in 2024, then slumped by 35.50% to $129,000 in 2025.
  • Its last three reported values are $129,000 in Q3 2025, $455,000 for Q2 2025, and $327,000 during Q1 2025.